Dr. Goran Olivecrona MD, PhD.
Consulting Cardiologist, University of Lund
Member of the Healthcare Council
Council Member Biography
Goran Olivecrona, MD, PhD, is a Senior Consultant in the Department of Cardiology at Lund University Hospital, Sweden. He has expertise in interventional cardiology, in particular treatment of acute coronary syndromes and cardiogenic shock with PCI as well as extensive experience in treating CTO's. He also implants percutaneous Aortic valves from both the apical and the femoral approach. Dr. Olivecrona' clinical research interest concerns cardiogenic shock, acute coronary syndromes, and therapeutic hypothermia both following cardiac arrest and in the course of myocardial infarction. He also has experience using novel chest compression devices during Cardiac arrest during PCI. Dr. Olivecrona' basic science research is in the mechanisms governing coronary circulation and reperfusion injury in myocardial infarction. He is the Principal Investigator in Sweden for several multi-center trials in interventional cardiology, including several trials with drug eluting stents. (This is me - Update Profile)
Employment History
- 1994 - Unspecified
- Consulting Cardiologist, University of Lund
GLG NewsSM Analyses by Goran Olivecrona(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
December 15, 2008
Retrospective studies should be viewed with caution. Most retrospective studies which may contain a bias in the prescribed treatment should be anlysed with matched propencity score. To confirm the results a randomized trial would essentially be needed.
-
A user friendly femoral access closure device with a fast learning curve
October 15, 2007
St. Jude Medical Announces Japanese Approval Of The Angio-Seal STS Plus Vascular Closure Device | www.medicalnewstoday.com
1. Angioseal is a very user friendly closure device which saves staff time spent with the patient and reduces he number of pseudoaneurysms, but it does not reduce the overall number of bleeding complications. 2. Angioiseal will probably continue to increase its market share in centers not moving to the radial access approach.
-
A new tool to improve survival rates in cardiac arrest victims?
October 15, 2007
Physio-Control Announces Availability Of LUCAS™ Chest Compression System In United States | www.medicalnewstoday.com
1. LUCAS can effectively sustain circulation in spite of cardiac arrest through external mechanical chest compressions thus maintaining a sustenance of blood flow to the brain during CPR. 2. Effective external mechanical chest compression devices like LUCAS, offer a new tool to aid in the treatment of cardiac arrest victims.
-
A New DES with less efficacy but maybe a better saftey profile is on the way.
October 11, 2007
FDA Panel Recommends Approval Of Medtronic Drug-Coated Stent | online.wsj.com
1. ENDEVOR subscribes to cardiologist concerned about the saftey profile of Current DES sold in the US (Cypher and TAXUS). 2. ENDEAVOR seems to carry a higher rate of binary restenosis than Cypher, but may have a lower rate of late stent subacute thrombosis (SAT) than either Taxus or cypher. 3. The impact on J&J and Boston will depend upon what results are seen in the forthcoming results of the ENDEAVOR IV study and also how the issue of Late Stent SAT will develop.
-
Another first generation DES enters the market
January 22, 2007
Boston Scientific Announces First Use Of PROMUS™ Everolimus-Eluting Stent System | www.medcompare.com
1. The PROMUS™ platform is a first generation DES composed of a “limus” drug and a durable polymer placed on cobalt-chromium alloy stent.
2. No large randomized trial data is yet available until presentation of the SPIRIT III data, a 1400 patient randomized trial.
3. PROMUS™ main niche may be better trackability than the other currently available DES on the market. Other than that, use cannot be recommended until after presentation of the SPIRIT III data.
Leading institutions connect with Goran Olivecrona through GLG
GLG Study Groups with Goran Olivecrona(?)
| Study Group Name | No. Members |
|---|---|
| Cardiologists (EU) | 829 |
| Interventional Cardiologists (EU) | 202 |
| Physicians who Implant Taxus Stents | 104 |
| Physicians who Implant Cypher Stents | 89 |
| Physicians who Implant Both Cypher and Taxus Stents | 86 |
GLG Live Meetings with Goran Olivecrona(?)
Goran Olivecrona has not participated in any GLG Live Meetings.